SLC2A3

Across TCGA pan-cancer cohorts, SLC2A3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC2A3 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SLC2A3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC2A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

ACC, UCEC, and KICH are the cancer types where SLC2A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
UCEC	DFS	Median	All	1.000	0.621	.002	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →
BLCA	DFS	Median	IV	1.000	0.189	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC2A3–ACC (DFS)

Open the ACC breakdown →